2024-11-07 03:38:11
Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Health/ 2023-07-22
Antengene Announces Dosing of First Pati...

SHANGHAI and PHILADELPHIA,April 14,2020-- Antengene announced today that it has dosed the first patient in Taiwan,China in its phase 1 open-...

Nucleus Network's 10 Step Guide to conducting Clinical Trials during a time of uncertainty
Health/ 2023-07-22
Nucleus Network's 10 Step Guide to ...

MELBOURNE,Australia,April 14,2020-- A new white paper,Undertaking Phase I ClinicalTrials in Australia During a Time of Uncertainty,has been ...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release